Status:
COMPLETED
Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors
Lead Sponsor:
Children's Oncology Group
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Childhood Extracranial Germ Cell Tumor
Childhood Extragonadal Malignant Germ Cell Tumor
Eligibility:
All Genders
Up to 21 years
Phase:
PHASE2
Brief Summary
This phase II trial is studying how well giving combination chemotherapy works in treating young patients with recurrent or resistant malignant germ cell tumors. Drugs used in chemotherapy, such as pa...
Detailed Description
PRIMARY OBJECTIVES: I. Determine the response rate in pediatric patients with recurrent or resistant malignant germ cell tumors (GCT) treated with paclitaxel, ifosfamide, and carboplatin. SECONDARY ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Histologically confirmed (at original diagnosis) extracranial germ cell tumor (GCT) containing 1 of the following malignant elements:
- Yolk sac tumor (endodermal sinus tumor)
- Choriocarcinoma
- Embryonal carcinoma
- Meets 1 of the following disease criteria:
- Recurrent malignant disease
- Chemotherapy-resistant disease
- Relapsed disease
- Disease refractory to conventional therapy
- Measurable disease
- Must have received a prior first-line chemotherapy regimen that included cisplatin
- Patients with tumor marker (AFP and/or BHCG) elevation alone or bone scan findings alone are not eligible\*
- Patients with immature teratoma (any grade), germinoma, sex-cord stromal tumors, or recurrent GCT previously treated with surgery alone are not eligible
- Karnofsky performance status (PS) 50-100% (age \> 16 years) OR Lansky PS 50-100% (age ≤ 16 years) OR ECOG PS 0-2
- Life expectancy ≥ 8 weeks
- Absolute neutrophil count ≥ 750/mm³
- Platelet count ≥ 75,000/mm³ (transfusion independent)
- Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min OR creatinine normal based on age/gender, as defined by the following:
- ≤ 0.4 mg/dL (1 month to \< 6 months of age)
- ≤ 0.5 mg/dL (6 months to \< 1 year of age)
- ≤ 0.6 mg/dL (1 to \< 2 years of age)
- ≤ 0.8 mg/dL (2 to \< 6 years of age)
- ≤ 1.0 mg/dL (6 to \< 10 years of age)
- ≤ 1.2 mg/dL (10 to \< 13 years of age)
- ≤ 1.4 mg/dL (13 to ≥ 16 years of age) (female)
- ≤ 1.5 mg/dL (13 to \< 16 years of age) (male)
- ≤ 1.7 mg/dL (≥ 16 years of age) (male)
- Bilirubin ≤ 1.5 times upper limit of normal (ULN) for age
- ALT \< 2.5 times ULN for age
- Shortening fraction ≥ 27% by echocardiogram OR ejection fraction ≥ 50% by gated radionuclide study
- No dyspnea at rest
- No exercise intolerance
- Pulse oximetry \> 94% (if there is clinical indication for determination)
- Patients with seizure disorder are eligible provided they are on non-enzyme inducing anticonvulsants and seizures are well controlled
- No CNS toxicity \> grade 2
- No active graft-versus-host disease
- No allergy to Cremophor EL or castor oil
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No other concurrent chemotherapy or immunomodulating agents
- Recovered from prior chemotherapy, immunotherapy, or radiotherapy
- At least 1 week since prior growth factors (2 weeks for pegfilgrastim)
- At least 1 week since prior biologic therapy
- At least 2 weeks since prior myelosuppressive chemotherapy (4 weeks for nitrosourea)
- At least 2 weeks since prior local palliative radiotherapy (i.e., small port)
- At least 6 months since prior craniospinal radiotherapy or radiotherapy to ≥ 50% of pelvis
- At least 6 weeks since other prior substantial bone marrow radiotherapy
- At least 6 months since prior allogeneic stem cell transplantation
- Concurrent radiotherapy to localized painful lesions allowed provided at least 1 measurable lesion is not irradiated
Exclusion
Key Trial Info
Start Date :
November 5 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2018
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00467051
Start Date
November 5 2007
End Date
June 30 2018
Last Update
August 29 2018
Active Locations (95)
Enter a location and click search to find clinical trials sorted by distance.
1
The University of Arizona Medical Center-University Campus
Tucson, Arizona, United States, 85724
2
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States, 72205
3
Kaiser Permanente Downey Medical Center
Downey, California, United States, 90242
4
Miller Children's and Women's Hospital Long Beach
Long Beach, California, United States, 90806